Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

Cyclacel Pharmaceuticals, Inc. (“Cyclacel”) (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines,  announced a change in control and leadership on February 26, 2025.

Datuk Dr. Doris Wong Sing Ee acquired the majority interest in Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) and will now serve as its Chief Executive Officer and Executive Director.

In a press release, Datuk Dr. Doris Wong Sing Ee said, “I am honored to serve as Cyclacel’s next CEO….I look forward to our exciting next chapter as I work with the rest of Cyclacel’s management team and board of directors to further build our biopharmaceutical business and deliver value for patients, shareholders and our other stakeholders.”

Rimon attorneys Debbie Klis and Marc C. Lee led this deal advising Datuk Dr. Doris Wong Sing Ee, with support from counsel, Olivia Wang and paralegal, Anne Mitzelfelt.

We congratulate Cyclacel Pharmaceuticals, Inc. and Datuk Dr. Doris Wong Sing Ee on this exciting milestone!

Read more here

Our Mergers and Acquisition attorneys advise clients on mergers, acquisitions, sale of control transactions, business combinations, takeover defenses, and joint ventures. We advise our clients through all stages of their transactions, from initial structuring through negotiation and close. Read more here